SequelSEC

Atea Pharmaceuticals, Inc. AVIR

Pharmaceutical Preparations · CIK 0001593899 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$351.37M
Fiscal year ended 2021-12-31
Operating income
$138.38M
Fiscal year ended 2021-12-31
Free cash flow
Unavailable
Fiscal year ended 2021-12-31

Atea Pharmaceuticals, Inc. (AVIR) reported revenue of $351.37M and net income of $121.19M for the fiscal year ended 2021-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Atea Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Atea Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Revenue$351.37M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$138.38M
Net income$121.19M
Research & development$167.20M
Weighted-average diluted sharesUnavailable
Pretax income$138.59M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$45.79M
Selling & marketingUnavailable

Balance

Atea Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Cash & equivalents$764.38M
Total assets$772.89M
Current assets$772.40M
Total liabilities$62.82M
Current liabilities$56.88M
Total equity incl. NCI$710.08M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$4.53M

Cash flow

Atea Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Operating cash flow-$87.00M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$1.46M
Net change in cash-$85.54M
Stock-based compensation$39.62M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$29.00K

Derived

Atea Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin39.4%
FCF marginUnavailable
SBC / revenue11.3%
Current ratio13.58x
Revenue YoY growthUnavailable
Net margin34.5%
R&D / revenue47.6%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AVIR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.